Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Baxter International ( (BAX) ) has provided an announcement.
On April 30, 2026, Baxter reported first-quarter 2026 results showing worldwide sales from continuing operations of about $2.7 billion, up 3% on a reported basis but down 1% organically, with U.S. revenue declining and international sales growing. The company posted a U.S. GAAP loss from continuing operations of $17 million, or $0.03 per diluted share, while adjusted EPS fell 35% to $0.36 as higher tariffs, manufacturing costs and unfavorable expense comparisons weighed on margins, and it reiterated a full-year outlook calling for roughly flat sales and adjusted EPS of $1.85 to $2.05.
Segment performance was mixed, with Medical Products & Therapies and Healthcare Systems & Technologies seeing modest reported declines on an organic basis, while Pharmaceuticals delivered 7% reported and 1% organic growth, aided by Drug Compounding. Baxter highlighted launches such as the IV Verify Line Labeling System, showcased new surgical and patient transport technologies, expanded its internal continuous improvement program with more than 230 initiatives in the quarter, announced a small quarterly dividend, and underscored its strategic focus on stabilizing operations and driving more consistent performance after the January 2025 divestiture of its Kidney Care business.
The most recent analyst rating on (BAX) stock is a Hold with a $18.49 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
The score is held down primarily by deteriorating financial performance (notably the 2025 revenue collapse and negative/weak cash generation) and a bearish technical setup (below key moving averages with negative MACD). Valuation provides only limited support due to a negative P/E despite a moderate dividend yield, while the latest earnings call indicates a back-half-weighted recovery but with substantial margin and execution risks (Novum disruption, tariffs, and Pharmaceuticals weakness).
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc., based in Deerfield, Ill., is a global medtech company providing connected solutions, medical devices and advanced injectable technologies used across hospitals, physician offices and other care settings. The company, which employs about 37,500 people, focuses on essential therapies and technologies that support millions of patients and healthcare providers worldwide.
Average Trading Volume: 9,533,509
Technical Sentiment Signal: Sell
Current Market Cap: $8.72B
For a thorough assessment of BAX stock, go to TipRanks’ Stock Analysis page.